OGN
BEARISH
$13.25
Live
Organon & Co. · NYSE
Target $11.25
(-15.1%)
$5.69
52W Range
$13.39
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated May 01, 2026
Market cap
$3.48B
P/E
14.1
ROE
30.6%
Profit margin
3.0%
Debt/Equity
11.7
Dividend yield
0.6%
AI Analysis
AI-powered fundamental assessment
Confidence
85%
OGN presents a high-risk profile characterized by a Piotroski F-Score of 4/9 (Stable) and a critical Debt/Equity ratio of 11.70. While the stock has experienced a massive speculative rally over the last 60 days, the current price of $13.25 is significantly decoupled from its Graham Number ($7.82) and Intrinsic Value ($6.58). Fundamental deterioration is evident in the -5.30% revenue growth and -30.4% YoY EPS growth, suggesting the recent price surge is not supported by operational performance.
Key Strengths
Strong Gross Margin (54.34%)
High ROE (30.56%), though likely inflated by high leverage
Healthy Current Ratio (1.82) providing short-term liquidity
Low Price-to-Sales ratio (0.56)
Extremely low Forward P/E (3.59) if earnings projections materialize
Key Risks
Extreme leverage with a Debt/Equity ratio of 11.70
Negative revenue growth (-5.30% YoY)
Significant overvaluation relative to Graham and Intrinsic values
Declining earnings performance (-30.4% YoY EPS growth)
Recent price spike (+121% in 1 month) suggests a speculative bubble
AI Fair Value Estimate
Based on comprehensive analysis
$7.2
-45.7% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
31
Weak
30
25
40
20
40
AI Verdict
Speculative Overvaluation
Key drivers: Extreme Debt/Equity ratio, Negative growth trends, Price-to-Intrinsic Value gap
Confidence
90%
Value
30/100
Ref P/E 14.10, Graham Number $7.82
Positives
- Low P/S ratio
Watchpoints
- Price $13.25 is ~70% above Graham Number $7.82
- Price is ~100% above Intrinsic Value $6.58
Future
25/100
Ref Growth rates
Positives
- Low Forward P/E suggests optimistic analyst projections
Watchpoints
- Negative YoY Revenue Growth (-5.30%)
- Negative YoY EPS Growth (-30.4%)
Past
40/100
Ref Historical trends
Positives
- Recent 6-month price recovery
Watchpoints
- 5-Year change of -51.2%
- Consistent earnings misses in recent quarters
Health
20/100
Ref Piotroski F-Score 4/9, Debt/Equity 11.70
Positives
- Current Ratio > 1.5
Watchpoints
- Debt/Equity of 11.70 is unsustainable
- Piotroski F-Score of 4/9 is barely stable
Dividend
40/100
Ref Yield 0.60%, Payout 47.22%
Positives
- Sustainable payout ratio (47.22%)
Watchpoints
- Negligible yield (0.60%)
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$13.25
Analyst Target
$11.25
Upside/Downside
-15.1%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for OGN and closest competitors.
Updated 2026-04-30
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
OGN
Organon & Co.
Primary
|
-51.2% | -37.9% | +3.5% | +102.7% | +121.2% | +54.1% |
|
ACAD
ACADIA Pharmaceuticals Inc.
Peer
|
-31.3% | +1.1% | +22.8% | -12.7% | -8.3% | -7.0% |
|
LIVN
LivaNova PLC
Peer
|
-22.5% | +45.9% | +83.9% | +23.9% | +0.8% | -1.6% |
|
LQDA
Liquidia Corporation
Peer
|
+1382.8% | +474.7% | +180.9% | +63.4% | +6.0% | +3.2% |
|
HNGE
Hinge Health, Inc.
Peer
|
+19.9% | +19.9% | +19.9% | -9.7% | +24.2% | +2.5% |
OGN
Organon & Co.
Primary
5Y
-51.2%
3Y
-37.9%
1Y
+3.5%
6M
+102.7%
1M
+121.2%
1W
+54.1%
ACA
ACADIA Pharmaceuticals Inc.
Peer
5Y
-31.3%
3Y
+1.1%
1Y
+22.8%
6M
-12.7%
1M
-8.3%
1W
-7.0%
LIV
LivaNova PLC
Peer
5Y
-22.5%
3Y
+45.9%
1Y
+83.9%
6M
+23.9%
1M
+0.8%
1W
-1.6%
LQD
Liquidia Corporation
Peer
5Y
+1382.8%
3Y
+474.7%
1Y
+180.9%
6M
+63.4%
1M
+6.0%
1W
+3.2%
HNG
Hinge Health, Inc.
Peer
5Y
+19.9%
3Y
+19.9%
1Y
+19.9%
6M
-9.7%
1M
+24.2%
1W
+2.5%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
14.1
Forward P/E
3.59
PEG Ratio
N/A
P/B Ratio
4.59
P/S Ratio
0.56
EV/Revenue
1.88
EV/EBITDA
7.07
Market Cap
$3.48B
Profitability
Profit margins and return metrics
Profit Margin
3.01%
Operating Margin
16.19%
Gross Margin
54.34%
ROE
30.56%
ROA
6.22%
Growth
Revenue and earnings growth rates
Revenue Growth
-5.3%
Earnings Growth
N/A
Q/Q Revenue Growth
-5.34%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
11.7
High debt
Current Ratio
1.82
Good
Quick Ratio
0.84
Poor
Cash/Share
$2.21
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$1.5B
Gross Margin
49.2%
Op. Margin
14.4%
Net Margin
-13.6%
Total Assets
$12.9B
Liabilities
$12.1B
Equity
$0.8B
Debt/Equity
16.11x
Operating CF
$0.1B
CapEx
$-0.1B
Free Cash Flow
$0.1B
FCF Yield
54%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-30
$0.71
-16.8% surprise
2026-02-12
$0.63
-13.3% surprise
2025-11-10
$1.01
+8.5% surprise
2025-08-05
$1.0
+6.4% surprise
Healthcare Sector Comparison
Comparing OGN against 582 companies in the Healthcare sector
(37 bullish, 181 neutral, 364 bearish)
P/E Ratio
14.1
This Stock
vs
71.85
Sector Avg
-80.4%
(Discount)
Return on Equity (ROE)
30.56%
This Stock
vs
-87.12%
Sector Avg
-135.1%
(Below Avg)
Profit Margin
3.01%
This Stock
vs
-16.02%
Sector Avg
-118.8%
(Weaker)
Debt to Equity
11.7
This Stock
vs
2.6
Sector Avg
+349.3%
(Higher)
Revenue Growth
-5.3%
This Stock
vs
120.93%
Sector Avg
-104.4%
(Slower)
Current Ratio
1.82
This Stock
vs
4.39
Sector Avg
-58.6%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
OGN
Organon & Co.
|
BEARISH | $3.48B | 14.1 | 30.6% | 3.0% | $13.25 | |
|
ACAD
ACADIA Pharmaceuticals Inc.
|
NEUTRAL | $3.51B | 8.96 | 39.9% | 36.5% | $20.61 | Compare |
|
LIVN
LivaNova PLC
|
NEUTRAL | $3.43B | - | -19.2% | -17.5% | $62.78 | Compare |
|
LQDA
Liquidia Corporation
|
NEUTRAL | $3.42B | - | -111.1% | -43.5% | $38.85 | Compare |
|
HNGE
Hinge Health, Inc.
|
NEUTRAL | $3.55B | - | -132.9% | -89.9% | $45.03 | Compare |
OGN
Organon & Co.
BEARISH
Mkt Cap
$3.5B
P/E
14.1
ROE
30.6%
Price
$13.25
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-31 | WALSH MATTHEW M | Chief Financial Officer | Stock Award | 33,593 | - |
| 2026-03-31 | ARJONA FERREIRA JUAN CAMILO | Officer | Stock Award | 13,431 | - |
| 2026-03-31 | KARP DANIEL | Officer | Stock Award | 18,053 | - |
| 2026-03-31 | STAHLER RACHEL A | Chief Technology Officer | Stock Award | 18,867 | - |
| 2026-03-31 | MORRISSEY JOSEPH T JR | Chief Executive Officer | Stock Award | 24,584 | - |
| 2026-03-31 | FALCIONE AARON | Officer | Stock Award | 17,925 | - |
| 2026-03-31 | NISITA VITTORIO | Officer | Stock Award | 13,000 | - |
| 2026-03-31 | WEAVER KIRKE | General Counsel | Stock Award | 18,513 | - |
| 2026-03-31 | HOLZBAUR LYNETTE | Officer | Stock Award | 10,967 | - |
| 2026-03-31 | DRINANE JULIANA PAPA | Officer | Stock Award | 16,451 | - |
| 2026-03-27 | WALSH MATTHEW M | Chief Financial Officer | Stock Award | 15,071 | - |
| 2026-03-27 | ARJONA FERREIRA JUAN CAMILO | Officer | Stock Award | 8,865 | - |
| 2026-03-27 | KARP DANIEL | Officer | Stock Award | 14,184 | - |
| 2026-03-27 | STAHLER RACHEL A | Chief Technology Officer | Stock Award | 8,200 | - |
| 2026-03-27 | MORRISSEY JOSEPH T JR | Chief Executive Officer | Stock Award | 9,752 | - |
WALSH MATTHEW M
Chief Financial Officer
2026-03-31
33,593 shares
ARJONA FERREIRA JUAN CAMILO
Officer
2026-03-31
13,431 shares
KARP DANIEL
Officer
2026-03-31
18,053 shares
STAHLER RACHEL A
Chief Technology Officer
2026-03-31
18,867 shares
MORRISSEY JOSEPH T JR
Chief Executive Officer
2026-03-31
24,584 shares
FALCIONE AARON
Officer
2026-03-31
17,925 shares
NISITA VITTORIO
Officer
2026-03-31
13,000 shares
WEAVER KIRKE
General Counsel
2026-03-31
18,513 shares
HOLZBAUR LYNETTE
Officer
2026-03-31
10,967 shares
DRINANE JULIANA PAPA
Officer
2026-03-31
16,451 shares
WALSH MATTHEW M
Chief Financial Officer
2026-03-27
15,071 shares
ARJONA FERREIRA JUAN CAMILO
Officer
2026-03-27
8,865 shares
KARP DANIEL
Officer
2026-03-27
14,184 shares
STAHLER RACHEL A
Chief Technology Officer
2026-03-27
8,200 shares
MORRISSEY JOSEPH T JR
Chief Executive Officer
2026-03-27
9,752 shares
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
8-K
8-K
DEF 14A
10-K
8-K
8-K
10-Q
8-K
8-K
8-K/A
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
HOLD
4 analysts
BNP Paribas
2026-04-29
Outperform
Neutral
Piper Sandler
2026-04-28
Underweight
Neutral
Barclays
2026-02-24
Underweight
Underweight
Barclays
2025-12-09
Underweight
JP Morgan
2025-11-11
Underweight
Underweight
Morgan Stanley
2025-11-11
Equal-Weight
Equal-Weight
Past News Coverage
Recent headlines mentioning OGN from our newsroom.
Newest → oldest
No matching news yet.